Combination therapy before surgery for kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Clear cell kidney cancer confirmed by biopsy before surgery.
- Tumor stage T1N0M0 or T2N0M0 with a R.E.N.A.L. score of 10 or higher, meaning the tumor is complex to remove.
- Age between 18 and 80 years old.
- Willing to have kidney-sparing surgery.
- Good overall health with an ECOG score of 0 or 1 (fully active or slightly limited).
- No spread to lymph nodes, no blood vessel involvement, and no metastasis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
This trial tests giving two medications (a PD-L1 inhibitor and anlotinib) before surgery for complex kidney cancer, to try to shrink the tumor enough that surgeons can remove just part of the kidney instead of the whole organ. The goal is to preserve kidney function and avoid dialysis.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial tests a new treatment given before surgery for kidney cancer that is at high risk of coming back. The goal is to see if the treatment shrinks the tumor or improves surgery outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus either lenvatinib or axitinib for people with advanced clear cell kidney cancer that continued to grow after the first treatment. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.